𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

✍ Scribed by Johan Askling; Ronald F. van Vollenhoven; Fredrik Granath; Pauline Raaschou; C. Michael Fored; Eva Baecklund; Christina Dackhammar; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T. Jacobsson; Staffan Lindblad; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
99 KB
Volume
60
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti–tumor necrosis factor α therapy and
Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif

Treatment with tumor necrosis factor inh
Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis
✍ Lotta Ljung; Julia F. Simard; Lennart Jacobsson; Solbritt Rantapää-Dahlqvist; Jo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

## Abstract ## Objective Rheumatoid arthritis (RA) is associated with an increased risk of ischemic heart disease, in both early and established RA. Data on the risk of ischemic heart disease in relation to therapy with tumor necrosis factor (TNF) antagonists (anti‐TNF) are conflicting in patients

Individualized monitoring of drug bioava
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b